Oral semaglutide bioavailability and its variability between people — a second dataset — setting out what I have, and where I think it stops being reliable.
Posting a small dataset on Oral semaglutide bioavailability. It is mine, it is uncontrolled, and the method is stated so it can be discounted appropriately.
What I would like is not agreement but a second dataset collected by someone with no stake in mine. If one exists I would rather read it than argue for this one.
The SOUL trial: cardiovascular outcomes trial for oral semaglutide in people with type 2 diabetes and cardiovascular disease or chronic kidney disease. It demonstrates that benefit appears to be a property of the molecule and exposure, not specific to the route.
This has been discussed before and I could not find the thread, so, again.
On post #3 — agreed on the reasoning, with one qualification.
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
This is the answer, and the reason it is the answer is the more useful part.
Oral versus injectable exposure: comparing a 14 mg oral dose with a 0.5 mg injectable dose is comparing apples to a different fruit. The oral bioavailability is low enough that dose numbers are an order of magnitude different and not directly comparable.
It reads as pedantry until the day it does not.
Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure variability in oral formulations is mentioned repeatedly in the discussions here.
Worth one more sentence than it usually gets.
Where the Oral semaglutide bioavailability reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Confirming post #9 from a second method, which matters more than confirming it from a second person.
Tablet integrity matters more than people expect for a formulation that depends on an absorption enhancer released at a particular place. Splitting or crushing is not a dose adjustment; it is a different product.
That is one dataset and I would not build a rule on it.
I had written a reply contradicting post #10 and deleted it. Here is what survived.
The thirty-minute wait before eating is not conservatism. Food in the stomach materially reduces absorption of the oral product, and the instruction exists because the pharmacokinetic studies measured how much.
Worth reading the earlier posts in this thread before acting on mine.
Oral semaglutide bioavailability is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Where I part company with post #15, and it is a narrow parting.
Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as though they were the same pharmaceutical problem is a category error.
Adding the measurement that post #16 says would settle it.
Dose numbers for oral formulations are not comparable to injectable ones. The 14 mg oral dose is not equivalent to any injectable dose in the traditional comparison sense. They are different formulations with different pharmacokinetics and cannot be put on the same scale.
The mechanism is plausible, which is not the same as established.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
The answer changed when I changed how I was measuring, which was informative.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
The reasoning is more useful than the number, which is why I have shown it.
Adding the boring version of Oral semaglutide bioavailability, because the interesting version keeps getting posted and the boring one is usually right.
Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.
Everything in post #19 holds. The case it does not cover is the one I have.
The gastrointestinal tolerability profile of the oral formulation is broadly similar in character to the injectable, which supports the effects being systemic rather than local irritation.
Narrowing post #19, because the general version has more than one answer.
SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing.
Why administration conditions matter for oral semaglutide and not for injectables: the oral formulation depends on a transient pH effect in the stomach. Anything that changes gastric pH or transit time changes absorption. Food does both.
Written in the hope of being told what I have missed.
Timing consistency matters more for oral dosing than for weekly injection, because absorption depends on the state of the stomach and the state of the stomach varies through the day.
Someone should write this up properly, and it should probably not be me.
Post #23 answers the question as asked. The question underneath it is different.
The practical argument for an oral is adherence, and the published adherence data is less flattering than the argument. Daily dosing with fasting requirements is not obviously easier than a weekly injection.
I am reporting what happened, not recommending it.
PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because they are not all the same question.
One more caveat and then I will stop qualifying: the sample selected itself.
Storage for a small molecule is a different problem from storage for a peptide: generally more robust, generally less temperature-sensitive, and generally more affected by humidity.
Take it as a starting point and not as a specification.
Anyone comparing published oral and injectable efficacy should check whether the comparison is within one trial or across two. Across two, the populations differ and the comparison is weak.
Worth saying I have only my own numbers here, and n is small.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
I would want the raw data before agreeing with my own summary of it.